Mesenchymal Stem Cells: a Potential Treatment Approach for Refractory Chronic Spontaneous Urticaria

Simple item page
dc.contributor.authorÖzgül Özdemir R.B.
dc.contributor.authorÖzdemir A.T.
dc.contributor.authorKırmaz C.
dc.contributor.authorOvalı E.
dc.contributor.authorÖlmez E.
dc.contributor.authorKerem H.
dc.contributor.authorEvrenos M.K.
dc.contributor.authorDeniz G.
dc.date.accessioned2024-07-22T08:06:04Z
dc.date.available2024-07-22T08:06:04Z
dc.date.issued2021
dc.description.abstractThe etiopathogenesis of chronic spontaneous urticaria (CSU) is not fully elucidated, and almost 30–40% of patients are resistant to treatments; therefore, there is still a need for the development of new and effective treatments. This study aimed to develop experimental cellular therapy for CSU patients resistant to current treatment options. Autologous adipose tissue mesenchymal stem cells (MSC) were administered to 10 refractory CSU patients who were then followed up for six months. The efficacy of treatment was evaluated according to the weekly urticaria activity scores (UAS7) and drug use scores (DUS7). To observe the effect of treatment on immune cells, CD4+ T cell subsets were analyzed by flow cytometry, and the serum IFN-γ, TNF-α, IL2, IL-4, IL-5, IL-6, IL-10, IL-13, IL-17a, IL-21, IL-22, TGF-β1, PGE2, IDO and anti-FcεRI levels were measured using the Luminex and ELISA methods. The values obtained were compared with 10 control refractory CSU patients and five healthy controls. We found that the T cell subsets and inflammatory molecules were not affected by MSC treatment during the follow-up period. In control patients, a significant decrease was detected only at the Th2 subset, TGF-β1, PGE2, IDO and anti-FcεRI levels on the 14th day of treatment. The UAS7 and DUS7 values of the MSC-treated patients significantly decreased during the follow-up period, but in control patients, a significant but temporary decrease was seen. According to our findings, unlike conventional treatment, MSC therapy resulted in longer and more effective recovery. Our data indicate that MSCs may be an alternative and effective approach for treatment-resistant CSU patients. [Figure not available: see fulltext.] © 2020, Springer Science+Business Media, LLC, part of Springer Nature.
dc.identifier.DOI-ID10.1007/s12015-020-10059-w
dc.identifier.issn26293269
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/13368
dc.language.isoEnglish
dc.publisherSpringer
dc.subjectChronic Urticaria
dc.subjectDinoprostone
dc.subjectHumans
dc.subjectMesenchymal Stem Cells
dc.subjectTransforming Growth Factor beta1
dc.subjectantinuclear antibody
dc.subjectcyclosporine
dc.subjectgamma interferon
dc.subjectimmunoglobulin E receptor
dc.subjectindoleamine 2,3 dioxygenase
dc.subjectinterleukin 10
dc.subjectinterleukin 13
dc.subjectinterleukin 17
dc.subjectinterleukin 2
dc.subjectinterleukin 21
dc.subjectinterleukin 22
dc.subjectinterleukin 4
dc.subjectinterleukin 5
dc.subjectinterleukin 6
dc.subjectomalizumab
dc.subjectprostaglandin E2
dc.subjectretinoid related orphan receptor gamma
dc.subjectthyroglobulin antibody
dc.subjectthyroid peroxidase antibody
dc.subjecttranscription factor GATA 3
dc.subjecttranscription factor T bet
dc.subjecttransforming growth factor beta1
dc.subjecttumor necrosis factor
dc.subjectprostaglandin E2
dc.subjecttransforming growth factor beta1
dc.subjectadipose tissue
dc.subjectadult
dc.subjectangioneurotic edema
dc.subjectArticle
dc.subjectautoimmunity
dc.subjectCD4+ T lymphocyte
dc.subjectcell stimulation
dc.subjectcell therapy
dc.subjectchemoluminescence
dc.subjectchronic urticaria
dc.subjectclinical article
dc.subjectclinical trial
dc.subjectcontrolled study
dc.subjectdisease duration
dc.subjectdrug use score
dc.subjectenzyme linked immunosorbent assay
dc.subjectfemale
dc.subjectflow cytometry
dc.subjecthelper cell
dc.subjecthuman
dc.subjecthuman cell
dc.subjectimmunocompetent cell
dc.subjectimmunomodulation
dc.subjectindirect fluorescent antibody technique
dc.subjectmale
dc.subjectmesenchymal stem cell
dc.subjectopen study
dc.subjectperipheral blood mononuclear cell
dc.subjectregulatory T lymphocyte
dc.subjectscoring system
dc.subjectskin allergy
dc.subjectskin disease assessment
dc.subjectskin test
dc.subjectT lymphocyte subpopulation
dc.subjectTh1 cell
dc.subjectTh17 cell
dc.subjectTh2 cell
dc.subjecturticaria activity score
dc.subjectchronic urticaria
dc.titleMesenchymal Stem Cells: a Potential Treatment Approach for Refractory Chronic Spontaneous Urticaria
dc.typeArticle

Files

Collections

Scopus Koleksiyonu